Lightnews — Scholar-powered news

John Zupancic

@johnzupancic.bsky.social

390 followers 320 following 69 posts

Neonatologist @bidmcneo and @harvardmed Babies | Health Services Research | Clinical Epidemiology connects.catalyst.harvard.edu/Profiles/display/Person/3581 ORCID: https://orcid.org/0000-0003-1734-7193 he/him/his posts = mine

orcid.org

Posts Media Videos Starter Packs

Pinned

John Zupancic @johnzupancic.bsky.social · Nov 16

As a welcome to our new BlueSky Friends, we just got a 30% discount code for the book below through Oxford University Press. Happy reading!
#NeoSky #NeoEBM

global.oup.com/academic/pro... and enter code AMPROMD9 at checkout

2 6 24

John Zupancic @johnzupancic.bsky.social · May 8

Lots more info (including state-specific relevant to your situation) at ccf.georgetown.edu and www.kff.org

1 3

John Zupancic @johnzupancic.bsky.social · May 8

3. That makes it one of our most important tools for ensuring equity (slide courtesy of Dr. Shah)

1 1 2

John Zupancic @johnzupancic.bsky.social · May 8

Dr. Shetal Shah (@nicubatman on Instagram and the Other place) Harvard BIDMC Newborn Epidemiology and HSR conference, reminding us that 1. Health insurance for all children is a civil right and 2. Medicaid is the single biggest payor for US births

2 4 8

Reposted by John Zupancic

Neena Modi @neenamodi1.bsky.social · Dec 17

COLLABORATE, coming 2025, will determine the effects of donor milk, formula, and cow-milk fortifier on surgical NEC, survival & cognition in extremely preterm babies, key questions parents & clinicians have been asking for many years. Explainer & summary here: www.imperial.ac.uk/neonatal-dat...

2 6

Reposted by John Zupancic

Neena Modi @neenamodi1.bsky.social · Dec 19

The National Neonatal Research Database is an amazing collaborative effort by all neonatal units in England, Scotland & Wales. Read our Christmas Newsletter here sway.cloud.microsoft/TRwgQx0jRac9... @99nicu.bsky.social @neonatalnursesuk.bsky.social @

Created using Microsoft Sway

COLLABORATE is an efficient, UK-wide, real-world-data-enabled, digital technology-facilitated, adaptive, group-sequential, 2-randomisation, controlled trial to determine clinical efficacy, effect size

sway.cloud.microsoft

4 5

Reposted by John Zupancic

Atul Malhotra @atulmalhotra.bsky.social · Dec 21

Sharing new paper from our workshop in #PAS2023

Navigating Information Overload on Social Media: Opportunities & Misadventures for Clinicians and Professionals www.newbornjournal.org/abstractArti...

@briankingneo.bsky.social @souvikneo.bsky.social

#neosky @ebneo.bsky.social @espr-esn.bsky.social

3 9

John Zupancic @johnzupancic.bsky.social · Dec 21

Bonus content: A fascinating interview about the paper with Drs. Philip Sunshine and William Northway
youtu.be/79prakcjBjc?...
6/6

Birth of BPD: A Conversation with Dr. William Northway, Dr. Philip Sunshine & Dr. David Cornfield

YouTube video by Stanford Medicine Children's Health

youtu.be

John Zupancic @johnzupancic.bsky.social · Dec 21

Case reports and series may be prone to bias, but in the hands of committed scientists, observation is still the entry point to improved outcome.
5/6

John Zupancic @johnzupancic.bsky.social · Dec 21

…including progression of disease with path, clinical, radiological lenses; very early discussion of acquired pulmonary hypertension; role of oxygen; separation of two overlapping disease entities with eventual demonstration of distinct treatment modalities.
4/6

John Zupancic @johnzupancic.bsky.social · Dec 21

For your consideration:
Careful description, with no statistical comparisons, still brought a number of lasting truths to the table in this first comprehensive description of BPD…
3/6

John Zupancic @johnzupancic.bsky.social · Dec 21

From the article: “The two outstanding findings are the prolongation of the healing phase of [RDS} and the appearance of a new chronic pulmonary syndrome that is associated with intermittent positive pressure respirators and High Oxygen for longer than one hundred and fifty hours (six days).”
2/6...

John Zupancic @johnzupancic.bsky.social · Dec 21

#52MoreChallenge Week 4!
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7):357. PMID: 5334613.
pubmed.ncbi.nlm.nih.gov/5334613/
#neoSky #neoEBM #52MoreChallenge
1/6...

1 1 3

John Zupancic @johnzupancic.bsky.social · Dec 21

ROBINS-I v2: www.riskofbias.info/welcome/robi...

Risk of bias tools - ROBINS-I V2 tool

We are pleased to announce Version 2 of the ROBINS-I tool, launched on 22 November 2024. Access the tool here: ROBINS-I V2 (editable document) or ROBINS-I V2 (PDF document) The Risk Of Bias In Non-...

www.riskofbias.info

John Zupancic @johnzupancic.bsky.social · Dec 21

GRADE obviously also supports this broadly within a given review at the body-of-literature level.

I am not sure that we have Cochrane NRSI SRMA examples in neonatology yet. Might be worth taking one on in the above area as a pilot?

1 2

John Zupancic @johnzupancic.bsky.social · Dec 21

But there has always been rx evidence beyond RCTs (just think what we got from the Framingham study). Cochrane has expanded its charter to non-randomised studies of the effects of interventions (NRSIs) and is developing tools to support that endeavor (eg see the observational RoB tool ROBINS-I v2)

1 2

John Zupancic @johnzupancic.bsky.social · Dec 21

It's such an important point @briankingneo.bsky.social . SRMAs with few or no RCTs are of course an essential part of the evidence synthesis process - I suspect that @souvikneo.bsky.social's review might find itself into the rationale for a new CIHR trial application or two :)

1 2

John Zupancic @johnzupancic.bsky.social · Dec 11

Great! Dr. Saigal is always happy to hear from people if you have questions or comments.

Reposted by John Zupancic

John Zupancic @johnzupancic.bsky.social · Nov 20

I guess it's not surprising that our organizations and journals must lag a bit in adoption of a new platform, but they are an important part of the conversation. Let's encourage whatever we're affiliated with to take the leap. We can log them here (currently pretty sparse)

go.bsky.app/DwfZqQF

13 25

Reposted by John Zupancic

European Society for Paediatric Research (ESPR) @espr-esn.bsky.social · Dec 10

🌟 Save the Date! 🌟
Join us for the inaugural Congress of the European Paediatric Academic Societies (CEPAS) in Lyon, France, from 28–31 October 2026. Mission: Uniting paediatric professionals to advance child health through cutting-edge research, education, and collaboration.👉Learn more at cepas.org

Congress of the European Paediatric Academic Societies 2026

Welcome to CEPAS 2026 where we unite paediatric professionals in advancing child health through cuttingedge research, education, and collaboration.

cepas.org

1 1

John Zupancic @johnzupancic.bsky.social · Dec 10

(The #52MoreChallenge is a follow-up of the #52in52RCTChallenge. We're currently replaying the first month from Twitter and will start new articles in week 5. If you have candidates for the 52 most important non-RCT articles in the #NeoSky literature, please let me know)

2 2

Reposted by John Zupancic

Brian King @briankingneo.bsky.social · Dec 10

The next AAP SONPM Journal Club is Thursday (December 12th) at 4:00 pm EST. Andrew Beverstock, neonatal fellow, will review the Diamond trial, with mentors Tanith Alexander (trial investigator) and Ariel Salas. #neosky #neoEBM
Register - tinyurl.com/c87skbeh
Trial- nejm.org/doi/full/10.10…

3 8 9

John Zupancic @johnzupancic.bsky.social · Dec 10

Follow-up bonus about follow-up: Dr. Saigal interviewed the now-adult members of the same cohort decades later for a less prosaic, and quite moving, book and accompanying videos. See a.co/d/411zd3u and www.youtube.com/@PreemieVoices (the latter with both 2014 and 2024 interviews)
🧵fin

1 2

John Zupancic @johnzupancic.bsky.social · Dec 10

From the paper: “Nevertheless, the vast majority of ELBW respondents view their health-related quality of life as quite satisfactory and are difficult to distinguish from controls."
🧵4/5

John Zupancic @johnzupancic.bsky.social · Dec 10

The participants in this work were part of a long-term, geographically-defined (and therefore low-selection-bias) cohort, also a significant contribution to a literature that had been (and remains) plagued by single-center, short-term studies.
🧵3/5

John Zupancic @johnzupancic.bsky.social · Dec 10

Dr. Saroj Saigal took to heart the insight that EBM includes not only critical appraisal but also patient values & preferences. Her research used tools f/ economics & psychology to demonstrate that patients & families may have different impressions of their own 'medical sequelae' than expected.
🧵2/5

1 1